Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy

End-stage dilated cardiomyopathy (DCM) is the leading cause of morbidity and mortality in patients with Duchenne Muscular Dystrophy (DMD). No studies are available on the effect of ivabradine on long-term outcomes in end-stage DMD/DCM.

Source: International Journal of Cardiology - January 17, 2019 Category: Cardiology Authors: Rachele Adorisio, Camilla Calvieri, Nicoletta Cantarutti, Adele D'Amico, Michela Catteruccia, Enrico Bertini, Anwar Baban, Sergio Filippelli, Gianluigi Perri, Antonio Amodeo, Fabrizio Drago Source Type: research